Differences a cikin Mini Transplants da Growth vs Malignancy Effect
Tsarin magungunan ƙwayoyin sel wanda ba na myeloablative, ko "kananan-transplants," sune sabon nau'i na allogeneic na jiki wanda aka sa a cikin jiki wanda ba sa buƙatar ɗaukar nauyin (shafewa) ƙwayar zuwa ƙananan sifofin sutura.
Yadda suke aiki
A cikin gargajiya na sassaukan kwayoyin halitta, an ba marasa lafiya sassauran maganin chemotherapy, tare da ko ba tare da radiation ba, don shafe, ko kuma "ɓoye," gawar.
Sa'an nan kuma an ba su wani jiko na kwayoyin halitta masu bada gudummawa don farfado da samar da jini da kuma rigakafi.
Bincike ya nuna cewa manyan kwayoyin chemotherapy da radiation da aka ba su a cikin suturar kwayoyin halitta bazai zama kawai abin da ke da alhakin nasarar da suke samu ba a maganin ciwon daji. Magungunan da ba a taɓa amfani da shi ba na myeloablative suna amfani da ƙananan maganin chemotherapy don cimma sakamako mai kyau.
Graft vs. Malignancy
Ka'idar da ke da nasaba da irin nasarar da ake samu na irin wannan shinge ana kiranta "laftattun-malignancy" (GVM), "sutura-ciki-da-tumo," ko "sakamako mai kama da cutar kankara". Da zarar mai ba da gudummawar kwayoyin halitta ya shiga cikin mai karɓa, tsarin "sabon" tsarin rigakafi ya gane cewa duk sauran kwayoyin cutar ciwon daji sune mahaukaci ne kuma ya hallaka su.
Bambanci Daga Myeloablative Stem Cell Transplants
Ƙananan myeloablative transplants ya bambanta da farko a abin da ya faru kafin a dashi. Idan aka kwatanta da medeloablative transplants, mini-transplants amfani da yawa ƙananan kuma ƙasa da mai guba na rigakafi na chemotherapy da radiation, bi da jiko na mai bayarwa Tsarin Kwayoyin.
Wannan tsari yana amfani da satar da aka yi wa mummunan sakamako yayin da yake da mawuyaci ga mai karɓa.
Kamar dai yadda tsaka-tsire na sifofin sifofi, ƙananan transplants suna ɗauke da hadarin sata da yaduwar cuta , wanda kwayoyin da aka sassauci suka gan su a matsayin kasashen waje da kuma kai hari.
Yana amfani
Irin wannan dashi zai iya zama wani zaɓi mai kyau ga marasa lafiya da suka tsufa ko kuma suna da wasu yanayin kiwon lafiya wanda zai sa su kasa yin hakuri da sakamakon ilimin cutar chemotherapy na yau da kullum.
Hanyoyin da ba a taɓa amfani da shi ba wanda zai iya magance marasa lafiya wanda ke cikin gafara da ciwon daji mai tsanani , irin su mikilogenous cutar sankarar bargo , ko kuma waɗanda suka sake komawa baya bayan da aka cire dashi cell cell.
Masu bincike kuma suna kallon nasarar ciwon kwayar cutar marasa lafiya wanda ba wanda ke da myeloablative a cikin marasa lafiya da ciwon tumuttuka masu tsari, irin su nono da koda, da sauran yanayin kiwon lafiya irin su sclerosis da yawa.
Tun da yake yana ɗaukar wani lokaci don ƙwayoyin da aka ba da girma, baza'a amfani dasu ba a lokacin da ciwon daji yake a cikin matakai mafi girma.
Amfani
An yi amfani da tsire-tsire-tsire-tsire marasa magungunta don magance nau'in cutar jini, ciki har da Hodgkin da lymphoma ba Hodgkin, myeloma , da cutar sankarar bargo. Hanyoyin amsawa sun bambanta a binciken.
Wannan sabon tsari ne, tare da na farko da aka yi a kasa da shekaru 20 da suka gabata, saboda haka akwai iyakokin bincike na tsawon lokaci don amfanin da hadarin da ke tattare da irin wannan dashi. Duk da haka, sakamakon farko na alamar sa ba da bege ga marasa lafiya wanda ba haka ba za su sami damar karɓar suturar sutura ba , musamman waɗanda ke tsakanin shekarun 50 zuwa 75.
Sources:
Neiss, D., Duffy, K. "Tsarin Magana na Canji" a cikin Ezzone, S. (2004) Harsoyin Hematopoietic Tsarin Gudanarwa: Dokar Kula da Nursing. Ƙungiyar Nursing Oncology. Pittsburg, PA (shafi na 13-21).
Duke Medicine. Jigarar Adult da Marrow Transplant. Nonablative Allogeneic Patient Transplant Handbook. https://www.dukemedicine.org/sites/www.dukemedicine.org/files/nonmyeloablative_allogeneic_transplant_patient_handbook.pdf
Kasamon, Y., Bolanos-Meade, J., Prince, G. et al. Ayyukan HLA-Haploidential Blood-Blood-Blood-Blocked Tsuntsaurarwa Tare da Matsanancin Bayanin Tsarin Mulki Cyclophosphamide a tsofaffi Matasan. Journal of Clinical Oncology . Agusta 10, 2015. (An buga a kan layi kafin a buga).